New views on the pathogenesis of high-grade pelvic serous carcinoma with suggestions for advancing future research

Gynecologic Oncology

Volumn 127, Issue 3, 2012, Pages 645-650

  Sherman, Mark E ^a   Guido, Richard ^b   Wentzensen, Nicolas ^a   Yang, Hannah P ^a   Mai, Phuong L ^a   Greene, Mark H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; FOLLITROPIN; GONADORELIN; INHIBIN; LUTEINIZING HORMONE; ORAL CONTRACEPTIVE AGENT; SEX HORMONE;

ABDOMINAL SURGERY; ANEUPLOIDY; APOPTOSIS; ASCITES; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER STAGING; CARCINOGENESIS; CARCINOMA; CARCINOMA IN SITU; CELL PROLIFERATION; CELL TRANSFER; CELL TRANSFORMATION; ENDOMETRIUM; ENZYME ACTIVITY; EPITHELIUM CELL; EX VIVO STUDY; GENE EXPRESSION; GENE MUTATION; GYNECOLOGIC CANCER; HIGH GRADE SEROUS CARCINOMA; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; IN VITRO STUDY; IN VIVO STUDY; LAPAROSCOPY; MUELLERIAN DUCT; NOTE; OVARIAN SURFACE EPITHELIUM; OVARIECTOMY; OVARY CANCER; OVARY CYST; OVULATION; PELVIS CANCER; PERITONEUM VEIN SHUNT; PREVALENCE; PRIORITY JOURNAL; PROTEOMICS; RNA GENE; SALPINGOOOPHORECTOMY; TUBAL INTRAEPITHELIAL CARCINOMA; TUMOR LOCALIZATION; TUMOR MICROENVIRONMENT; TUMOR VOLUME; UTERINE TUBE CARCINOMA; UTERINE TUBE MUCOSA;

EID: 84868546391     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.08.023     Document Type: Editorial

References (50)

1. M. Choi, C.D. Fuller, C.R. Thomas Jr., and S.J. Wang Conditional survival in ovarian cancer: results from the SEER dataset 1988-2001 Gynecol Oncol 109 2008 203 209
2. S.S. Buys, E. Partridge, A. Black, C.C. Johnson, L. Lamerato, and C. Isaacs Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial JAMA 305 2011 2295 2303
3. R.J. Kurman, and Ie M. Shih Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer - shifting the paradigm Hum Pathol 42 2011 918 931
4. L. Dubeau The cell of origin of ovarian epithelial tumours Lancet Oncol 9 2008 1191 1197
5. C.P. Crum, F.D. McKeon, and W. Xian The oviduct and ovarian cancer: causality, clinical implications, and "targeted prevention" Clin Obstet Gynecol 55 2012 24 35
6. J.M. Piek, P.J. van Diest, R.P. Zweemer, J.W. Jansen, R.J. Poort-Keesom, and F.H. Menko Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer J Pathol 195 2001 451 456
7. N. Auersperg, A.S. Wong, K.C. Choi, S.K. Kang, and P.C. Leung Ovarian surface epithelium: biology, endocrinology, and pathology Endocr Rev 22 2001 255 288
8. M.E. Sherman, J.S. Lee, R.T. Burks, J.P. Struewing, R.J. Kurman, and P. Hartge Histopathologic features of ovaries at increased risk for carcinoma. A case-control analysis Int J Gynecol Pathol 18 1999 151 157
9. B.A. Werness, A.M. Afify, K.L. Bielat, G.H. Eltabbakh, M.S. Piver, and J.M. Paterson Altered surface and cyst epithelium of ovaries removed prophylactically from women with a family history of ovarian cancer Hum Pathol 30 1999 151 157
10. L. Resta, S. Russo, G.A. Colucci, and J. Prat Morphologic precursors of ovarian epithelial tumors Obstet Gynecol 82 1993 181 186
11. S.B. Gusberg, and L. Deligdisch Ovarian dysplasia. A study of identical twins Cancer 54 1984 1 4
12. S.C. Plaxe, L. Deligdisch, P.R. Dottino, and C.J. Cohen Ovarian intraepithelial neoplasia demonstrated in patients with stage I ovarian carcinoma Gynecol Oncol 38 1990 367 372
13. K.R. Mittal, A. Zeleniuch-Jacquotte, J.L. Cooper, and R.I. Demopoulos Contralateral ovary in unilateral ovarian carcinoma: a search for preneoplastic lesions Int J Gynecol Pathol 12 1993 59 63
14. B. Pothuri, M.M. Leitao, D.A. Levine, A. Viale, A.B. Olshen, and C. Arroyo Genetic analysis of the early natural history of epithelial ovarian carcinoma PLoS One 5 2010 e10358
15. P.L. Mai, SM, M. Piedmonte, B. Ioffe, B.M. Ronnett, and L.V. Le Pathological findings at risk-reducing salpingoophorectomy among women at increased ovarian cancer risk: results from GOG-199 [Abstract] J Clin Oncol 2012 1519 [Suppl.]
16. R.A. Ambros, M.E. Sherman, C.M. Zahn, P. Bitterman, and R.J. Kurman Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation Hum Pathol 26 1995 1260 1267
17. M.E. Sherman, P. Bitterman, N.B. Rosenshein, G. Delgado, and R.J. Kurman Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features Am J Surg Pathol 16 1992 600 610
18. E.A. Jarboe, A. Miron, J.W. Carlson, M.S. Hirsch, D. Kindelberger, and G.L. Mutter Coexisting intraepithelial serous carcinomas of the endometrium and fallopian tube: frequency and potential significance Int J Gynecol Pathol 28 2009 308 315
19. J.T. Rabban, M. Barnes, L.M. Chen, C.B. Powell, B. Crawford, and C.J. Zaloudek Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma Am J Surg Pathol 33 2009 1125 1136
20. C.B. Powell, E. Kenley, L.M. Chen, B. Crawford, J. McLennan, and C. Zaloudek Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy J Clin Oncol 23 2005 127 132
21. J.T. Rabban, E. Krasik, L.M. Chen, C.B. Powell, B. Crawford, and C.J. Zaloudek Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol Am J Surg Pathol 33 2009 1878 1885
22. F. Medeiros, M.G. Muto, Y. Lee, J.A. Elvin, M.J. Callahan, and C. Feltmate The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome Am J Surg Pathol 30 2006 230 236
23. K. Visvanathan, R. Vang, P. Shaw, A. Gross, R. Soslow, and V. Parkash Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study Am J Surg Pathol 35 2011 1766 1775
24. Y. Lee, A. Miron, R. Drapkin, M.R. Nucci, F. Medeiros, and A. Saleemuddin A candidate precursor to serous carcinoma that originates in the distal fallopian tube J Pathol 211 2007 26 35
25. D.W. Kindelberger, Y. Lee, A. Miron, M.S. Hirsch, C. Feltmate, and F. Medeiros Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship Am J Surg Pathol 31 2007 161 169
26. S.V. Nicosia, G.D. Wilbanks, B. Saunders, J. Mayer, R.J. Cardosi, and P.A. Kruk Cytology of human ovarian surface epithelial brushings Cancer 102 2004 1 10
27. B. Rungruang, B.L. Hood, M. Sun, E. Hoskins, T.P. Conrads, and K.K. Zorn Novel surgical approaches for sampling the ovarian surface epithelium and proximal fluid proteome J Proteome Res 9 2010 6071 6076
28. P. Hartge, R. Hayes, D. Reding, M.E. Sherman, P. Prorok, and M. Schiffman Complex ovarian cysts in postmenopausal women are not associated with ovarian cancer risk factors: preliminary data from the Prostate, Lung, Colon, and Ovarian cancer Screening Trial Am J Obstet Gynecol 183 2000 1232 1237
29. I. Cass, A. Walts, and B.Y. Karlan Does risk-reducing bilateral salpingo-oophorectomy leave behind residual tube? Gynecol Oncol 117 2010 27 31
30. S. Tang, K. Onuma, P. Deb, E. Wang, A. Lytwyn, and M. Sur Frequency of serous tubal intraepithelial carcinoma in various gynecologic malignancies: a study of 300 consecutive cases Int J Gynecol Pathol 31 2012 103 110
31. C.L. Pearce, K. Chung, M.C. Pike, and A.H. Wu Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin Cancer 115 2009 531 539
32. V. Beral, R. Doll, C. Hermon, R. Peto, and G. Reeves Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls Lancet 371 2008 303 314
33. P.O. Brown, and C. Palmer The preclinical natural history of serous ovarian cancer: defining the target for early detection PLoS Med 6 2009 e1000114
34. M.H. Greene, M. Piedmonte, D. Alberts, M. Gail, M. Hensley, and Z. Miner A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study Cancer Epidemiol Biomarkers Prev 17 2008 594 604
35. M.S. Yates, L.A. Meyer, M.T. Deavers, M.S. Daniels, E.R. Keeler, and S.C. Mok Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis Cancer Prev Res (Phila) 4 2011 463 470
36. J.D. Seidman, P. Zhao, and A. Yemelyanova "Primary peritoneal" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer Gynecol Oncol 120 2011 470 473
37. J.W. Carlson, A. Miron, E.A. Jarboe, M.M. Parast, M.S. Hirsch, and Y. Lee Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention J Clin Oncol 26 2008 4160 4165
38. A. Finch, M. Beiner, J. Lubinski, H.T. Lynch, P. Moller, and B. Rosen Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation JAMA 296 2006 185 192
39. J.L. Rutter, S. Wacholder, A. Chetrit, F. Lubin, J. Menczer, and S. Ebbers Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study J Natl Cancer Inst 95 2003 1072 1078
40. I.G. Schauer, A.K. Sood, S. Mok, and J. Liu Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer Neoplasia 13 2011 393 405
41. W. Shan, G. Yang, and J. Liu The inflammatory network: bridging senescent stroma and epithelial tumorigenesis Front Biosci 14 2009 4044 4057
42. A.F. Saad, W. Hu, and A.K. Sood Microenvironment and pathogenesis of epithelial ovarian cancer Horm Cancer 1 2010 277 290
43. P.C. Leung, and J.H. Choi Endocrine signaling in ovarian surface epithelium and cancer Hum Reprod Update 13 2007 143 162
44. S. Paget The distribution of secondary growths in cancer of the breast. 1889 Cancer Metastasis Rev 8 1989 98 101
45. D. Tarin, J.E. Price, M.G. Kettlewell, R.G. Souter, A.C. Vass, and B. Crossley Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts Cancer Res 44 1984 3584 3592
46. M.P. Iwanicki, R.A. Davidowitz, M.R. Ng, A. Besser, T. Muranen, and M. Merritt Ovarian cancer spheroids use myosin-generated force to clear the mesothelium Cancer Discov 1 2011 144 157
47. K.M. Nieman, H.A. Kenny, C.V. Penicka, A. Ladanyi, R. Buell-Gutbrod, and M.R. Zillhardt Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth Nat Med 17 2011 1498 1503
48. A.A. Jazaeri, J.L. Bryant, H. Park, H. Li, N. Dahiya, and M.H. Stoler Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma Neoplasia 13 2011 899 911
49. A.M. Karst, K. Levanon, and R. Drapkin Modeling high-grade serous ovarian carcinogenesis from the fallopian tube Proc Natl Acad Sci U S A 108 2011 7547 7552
50. K. Levanon, V. Ng, H.Y. Piao, Y. Zhang, M.C. Chang, and M.H. Roh Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis Oncogene 29 2010 1103 1113